Literature DB >> 8319074

Short communication: adverse chronic effects of high-dose irradiation on proximal bronchus in patients treated for bronchogenic carcinoma.

K Hayakawa1, N Mitsuhashi, Y Saito, N Nakajima, H Niibe.   

Abstract

Of five patients with epidermoid carcinoma of the lung who were treated with small fields of 80 Gy in 40 fractions/8-11 weeks (TDF123-129) to the hilar region, four patients developed marked stenosis of the proximal bronchi without tumour progression and died of pulmonary insufficiency 1-3 years after radiotherapy. These results should serve as a warning against escalation of the radiation dose, and the upper optimal dose might prove to be less than 80 Gy for the treatment of pulmonary hilar lesions.

Entities:  

Mesh:

Year:  1993        PMID: 8319074     DOI: 10.1259/0007-1285-66-785-477

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  4 in total

1.  [Caution with hypofractionated dose-escalating radiotherapy in non-small cell lung cancer].

Authors:  Julia Philipp; Michael Baumann
Journal:  Strahlenther Onkol       Date:  2014-06       Impact factor: 3.621

2.  Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy.

Authors:  Hui Liu; Xu Zhang; Yevgeniy Y Vinogradskiy; Stephen G Swisher; Ritsuko Komaki; Joe Y Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-27       Impact factor: 7.038

Review 3.  Inoperable localized stage I and stage II non-small-cell lung cancer.

Authors:  Eric L Gressen; Walter J Curran
Journal:  Curr Treat Options Oncol       Date:  2002-02

4.  Dosimetric evaluation of the feasibility of stereotactic body radiotherapy for primary lung cancer with lobe-specific selective elective nodal irradiation.

Authors:  Tetsuya Komatsu; Etsuo Kunieda; Tadashi Kitahara; Takeshi Akiba; Ryuta Nagao; Tsuyoshi Fukuzawa
Journal:  J Radiat Res       Date:  2015-11-12       Impact factor: 2.724

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.